The alternative text for this image may have been generated using AI. Figure 2: CD14-dependent activation of NFAT in BMDCs after LPS treatment. The alternative text for this image may have been ...
Clinical and analytical performance of non-small cell lung cancer biomarkers. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full text component ...
A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with ...
Philadelphia, PA, April 13, 2017 - Inflammatory bowel disease (IBD), characterized by chronic relapsing inflammation of the gut, is a common problem in the industrialized world. However, how IBD ...
Economic impact of progressive disease (PD) following frontline therapy in classical Hodgkin lymphoma (HL). This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not ...
PERTH, Australia – Implicit Bioscience Ltd.’s lead candidate, IC-14, is the first anti-CD14 monoclonal antibody (MAb) to progress to the clinic as it enters a phase II trial in the U.S. in COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results